Paper40940908
Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?
Ceniceros L and 7 others. Cancers (Basel), 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next? Papers, record 40940908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940908
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14534886 | Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. | Cancer | 2003 | https://conductscience.org/library/papers/14534886 | PubMed |
| 2 | 19809471 | The functional plasticity of T cell subsets. | Nat Rev Immunol | 2009 | https://conductscience.org/library/papers/19809471 | PubMed |
| 3 | 34998048 | Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. | Eur J Cancer | 2022 | https://conductscience.org/library/papers/34998048 | PubMed |
| 4 | 32461347 | Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32461347 | PubMed |
| 5 | 34907910 | Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. | J Clin Invest | 2021 | https://conductscience.org/library/papers/34907910 | PubMed |
| 6 | 28928458 | Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. | Nat Commun | 2017 | https://conductscience.org/library/papers/28928458 | PubMed |
| 7 | 35680043 | Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35680043 | PubMed |
| 8 | 36681415 | Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/36681415 | PubMed |
| 9 | 40381735 | Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. | J Hepatol | 2025 | https://conductscience.org/library/papers/40381735 | PubMed |
| 10 | 31875970 | Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. | Hepatology | 2020 | https://conductscience.org/library/papers/31875970 | PubMed |
| 11 | 35311147 | Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35311147 | PubMed |
| 12 | 24136146 | Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. | Br J Cancer | 2013 | https://conductscience.org/library/papers/24136146 | PubMed |
| 13 | 35621637 | Immune Checkpoint Inhibitors in Cancer Therapy. | Curr Oncol | 2022 | https://conductscience.org/library/papers/35621637 | PubMed |
| 14 | 32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416072 | PubMed |
| 15 | 27095655 | Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). | Nat Rev Gastroenterol Hepatol | 2016 | https://conductscience.org/library/papers/27095655 | PubMed |
| 16 | 32359091 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. | Int J Cancer | 2020 | https://conductscience.org/library/papers/32359091 | PubMed |
| 17 | 29405274 | Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. | Br J Surg | 2018 | https://conductscience.org/library/papers/29405274 | PubMed |
| 18 | 31535160 | Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. | Cancer Immunol Immunother | 2019 | https://conductscience.org/library/papers/31535160 | PubMed |
| 19 | 38493667 | Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT). | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38493667 | PubMed |
| 20 | 28975832 | Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. | Cancer Control | 2017 | https://conductscience.org/library/papers/28975832 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42169927 | Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42169927 | PubMed |
| 41639545 | Surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a narrative review of principles, technical nuances, and emerging strategies. | J Liver Cancer | 2026 | https://conductscience.org/library/papers/41639545 | PubMed |
| 41394868 | Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41394868 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40940908
GET https://conductscience.org/api/papers/v1/40940908/references?page=2